EndoTic - Endothelium and Ticagrelor

EndoTic - Endothelium and Ticagrelor: Pharmacological Effects Beyond Antiplatelet Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02244710

Enrollment

109

Registered

2014-09-19

Start date

2015-03-31

Completion date

2016-09-30

Last updated

2016-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome (ACS)

Keywords

Circulating Endothelial Cells, Endothelial Progenitor Cells, Acute coronary syndrome (ACS), Ticagrelor

Brief summary

Randomized clinical trial to assess the influence of treatment with ticagrelor or clopidogrel in the number of CECs (Circulating Endothelial Cells) and EPCs (Endothelial Progenitor Cells) in patients with ACS (Acute Coronary Syndrome), from baseline levels to chronic levels (1 month).

Detailed description

ACS Patients in both treatment groups will be assessed: Baseline, 48h and 1 month cell counts will be done for CECs and EPCs Platelet Function at 48h and 1month Adverse Events, ECG and blood testing result will be also collected

Interventions

DRUGTicagrelor vs Clopidogrel

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Willing to sign Informed Consent Form * 18 yr or older * Male and female (post menopause or contraception treatment) * ACS diagnosed with elevation of myocardial infarction biomarkers (as of 3rd Universal Definition of MI) * Planned invasive strategy (coronariography performed within 72hrs after admission)

Exclusion criteria

* Aspirin, clopidogrel or ticagrelor allergy. * Hemorrhagic diathesis or very high risk of bleeding. * Current treatment with oral anticoagulants, thienopyridines or ticagrelor. * Limited life expectancy. * Elective surgery planned. * High chance of not being able to complete the follow-up period.

Design outcomes

Primary

Measure	Time frame	Description
Number of cells	Baseline	EPC (Endothelial Progenitor Cells) CEC (Circulating Endothelial Cells)

Secondary

Measure	Time frame	Description
Platelet reactivity	At the time of coronary angiography	As determined by P2Y12 kits, VerifyNow®

Other

Measure	Time frame	Description
Safety: Bleeding and ischemic adverse events	18 months (Study duration)	Adverse Events collection

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026